These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effects of exogenous glucagon-like peptide-1 on the blood pressure, heart rate, mesenteric blood flow, and glycemic responses to intraduodenal glucose in healthy older subjects.
    Author: Trahair LG, Horowitz M, Hausken T, Feinle-Bisset C, Rayner CK, Jones KL.
    Journal: J Clin Endocrinol Metab; 2014 Dec; 99(12):E2628-34. PubMed ID: 25210879.
    Abstract:
    CONTEXT: Studies relating to the cardiovascular effects of glucagon-like peptide-1 (GLP-1) and its agonists, which slow gastric emptying, have not discriminated between fasting and postprandial, blood pressure (BP) and heart rate (HR). OBJECTIVE: To determine whether exogenous GLP-1 modulates the effects of an intraduodenal (ID) glucose infusion on BP, HR, and splanchnic blood flow in healthy older subjects. DESIGN: A double-blind randomized trial was conducted. SETTING: Community-dwelling residents attended a clinical research laboratory. PATIENTS: Ten healthy "older" subjects (9 male, 1 female; age 73.2 ± 1.5 y) were studied. INTERVENTIONS: Intravenous infusion of GLP-1 (0.9 pmol/kg/min), or saline (0.9%) for 90 min (t = -30-60 min). Between t = 0-60 min, ID glucose was infused at 3 kcal/min. MAIN OUTCOME MEASURES: BP, HR, superior mesenteric artery (SMA) flow, blood glucose, and serum insulin were measured. RESULTS: During the fasting period (t = -30-0 min), GLP-1 had no effect on BP or HR. In response to ID glucose (t = 0-60 min), systolic BP decreased (P < .001), and both HR (P < .001) and SMA flow (P < .05) increased, on both days. GLP-1 attenuated the maximum decrease in systolic BP (P < .05), tended to increase HR (P = .09), and increased SMA flow (P < .01). GLP-1 diminished the glycemic response (P < .05). CONCLUSIONS: In healthy older subjects, acute administration of GLP-1 attenuates the hypotensive response to ID glucose, and potentiates the increase in SMA flow.
    [Abstract] [Full Text] [Related] [New Search]